BSM-1516 / Blacksmith Medicines - LARVOL DELTA

Blacksmith Medicines Announces Presentation at AACR Annual Meeting 2025 (PRNewswire) - "Blacksmith Medicines, Inc...announced the company will present data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 at the McCormick Place Convention Center, Chicago, IL."

Preclinical • Oncology

Novel selective FEN1 nuclease inhibitor shows synergy with PARP-targeting drugs (AACR 2025) - "Safety of BSM-1516 was assessed in vitro in lineage-specific differentiation of human hematopoietic CD34+ progenitor cells and in vivo in mice at a daily dose of 120 mg/kg PO and 90 mg/kg IP for 7 days and revealed no signs of hematological toxicity. These collective data support further in vivo testing in PD and efficacy studies either as a single agent or in combination with PARPi."

Oncology • BRCA1 • BRCA2 • CD34 • FEN1 • LIG3 • LRIG1 • PCNA • RPA2 • XRCC1

Blacksmith Medicines to Present Preclinical Oncology Data at 8th DDR Inhibitors Summit (PRNewswire) - "Blacksmith Medicines...announced today that it will present preclinical data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the 8th DDR Inhibitors Summit taking place January 28th – 30th in Boston, MA....'During the presentation we will highlight strong synergy between our novel FEN1 inhibitor and existing DDR drug classes underscoring its potential to enhance the therapeutic effects of existing DDR-targeting treatments'."

Preclinical • Oncology

Small molecule inhibitor of FEN1 nuclease utilizing a novel metal-binding pharmacophore synergizes with inhibitors of USP1, PARP, PARG and ATR (AACR 2024) - "Synergistic relationships of BSM-1516 and its combination potential were further explored in viability studies with a panel of DDR inhibitors (n=25) in BRCA2-proficient and deficient cell lines. Strong synergy was identified with multiple drug classes that included inhibitors of USP1 (KSQ-4279), PARP (Olaparib, Niraparib, Talazoparib, AZD5305), PARG (PDD 00017273) and ATR (AZD6738, VE-822, Elimusertib).In vitro ADME assays and in vivo PK studies showed that BSM-1516 has properties suitable for in vivo testing, either as a single agent or in combination with synergistic DDR inhibitors, an investigation that is currently underway."

Oncology • BRCA2 • FEN1 • RPA2 • USP1

Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024 (PRNewswire) - "Blacksmith Medicines, Inc...announced preclinical data on its oncology program targeting flap endonuclease 1 (FEN1), a structure-specific metallonuclease that cleaves 5' DNA flaps during replication and repair, at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA....In vitro ADME assays and in vivo PK studies showed that BSM-1516 has properties suitable for in vivo testing, either as a single agent or in combination with synergistic DDR inhibitors, an investigation that is currently underway."

Preclinical • Oncology

Blacksmith Medicines Announces Upcoming Presentation at AACR Annual Meeting 2024 (PRNewswire) - "Blacksmith Medicines, Inc...today announced the company will present data on its oncology program targeting flap endonuclease 1 (FEN1)...at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 at the San Diego Convention Center, San Diego CA."

Preclinical • Oncology